<DOC>
	<DOCNO>NCT00088933</DOCNO>
	<brief_summary>This randomized phase I trial study side effect , best way give , best dose docetaxel give together vaccine therapy sargramostim treat patient metastatic lung cancer metastatic colorectal cancer . Vaccines may make body build immune response kill tumor cell . Colony-stimulating factor sargramostim increase number immune cell find bone marrow peripheral blood . Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . Combining vaccine therapy sargramostim docetaxel may kill tumor cell .</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim With Without Docetaxel Treating Patients With Metastatic Lung Cancer Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine recommend dose schedule docetaxel give combination recombinant vaccinia-CEA-TRICOM vaccine , recombinant fowlpox-CEA-TRICOM vaccine , sargramostim ( GM-CSF ) , define best immune response acceptable toxicity , patient carcinoembryonic antigen ( CEA ) -expressing metastatic lung colorectal cancer . II . Compare effect vary dos schedule docetaxel CEA-specific T-cell immune response ELISPOT assay patient treat regimen . III . Compare objective antitumor response patient treat regimen . OUTLINE : This 2-part , randomize , pilot study . Patients randomize 1 6 treatment arm : arm I , II , III part I ( lung cancer colorectal cancer patient ) arm IV , V , VI part II ( lung cancer patient ) . Patients stratify accord disease site HLA-A2 positivity ( positive v negative ) . At least 6 10 patient must HLA-A2 positive treatment arm . Vaccinia-CEA-TRICOM vaccine ( part I II ) : In treatment arm , patient receive vaccinia-CEA-TRICOM vaccine intradermally day 1 sargramostim ( GM-CSF ) subcutaneously ( SC ) vaccine site day 1-4 . Fowlpox-CEA-TRICOM vaccine concurrent chemotherapy : Part I ( lung cancer colorectal cancer patient ) : ARM 1 : Three week treatment vaccinia-CEA-TRICOM vaccine , patient receive fowlpox-CEA-TRICOM vaccine SC day 1 GM-CSF SC vaccination site day 1-4 . ARM II : Patients receive fowlpox-CEA-TRICOM vaccine GM-CSF arm I lower-dose docetaxel IV 30 minute day 1 8 . ARM III : Patients receive fowlpox-CEA-TRICOM vaccine GM-CSF arm I standard-dose docetaxel IV 30 minute day 1 8 . Part II ( lung cancer patient ) : ARM IV : Patients receive fowlpox-CEA-TRICOM vaccine GM-CSF arm I full-dose docetaxel IV 1 hour day 1 . ARM V : Patients receive full-dose docetaxel IV 1 hour day 1 , fowlpox-CEA-TRICOM vaccine SC day 8 , GM-CSF SC vaccination site day 8-11 . ARM VI : Patients receive full-dose docetaxel arm V , fowlpox-CEA-TRICOM vaccine SC day 15 , GM-CSF SC vaccination site day 15-18 . Treatment arm repeat every 21 day total 4 course absence disease progression unacceptable toxicity . Patients significant disease progression unacceptable toxicity 4 course treatment may receive additional fowlpox-CEA-TRICOM vaccine docetaxel accord treatment arm enrol study entry . Patients follow every 6 month 2 year annually 13 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Histologically confirm lung OR colorectal cancer Incurable metastatic disease Currently available standard treatment likely offer survival advantage result superior palliation Evaluable disease radiograph Tumor must currently express carcinoembryonic antigen ( CEA ) immunohistochemistry OR CEA &gt; = 10 ng/mL point disease course No clinically active brain metastasis Must first secondline treatment OR decline secondline treatment ( part I ) Patients colon cancer must offer treatment oxaliplatin ( part I ) ECOG 01 Life expectancy least 4 month Absolute neutrophil count &gt; = 1,500/mm^3 WBC &gt; = 3,000/mm^3 Platelet count &gt; = 100,000/mm^3 Bilirubin normal Meets 1 follow criterion : SGOT SGPT = &lt; 2.5 time upper limit normal ( ULN ) AND alkaline phosphatase normal SGOT SGPT = &lt; normal AND alkaline phosphatase = &lt; 4.0 time ULN Hepatitis B C negative clinical history physical exam Creatinine = &lt; 1.5 mg/dL OR creatinine clearance &gt; = 60 mL/min Proteinuria = &lt; grade 1 No know suspect history impaired cardiac function evidence baseline echocardiogram Adequate pulmonary function No history clinical evidence immune deficiency autoimmunity HIV negative No history concurrent diagnosis follow : Altered immunodeficiency Eczema eczematoid skin disorder Acute , chronic , exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) No history allergy untoward reaction prior vaccination vaccinia virus No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No history allergy egg egg product No frequent vomit severe anorexia No inflammatory bowel disease No Crohn 's disease No ulcerative colitis No active diverticulitis Neuropathy = &lt; grade 1 ( sensory neuropathy ) No uncontrolled seizure disorder No encephalitis No multiple sclerosis Must maintain reasonable state nutrition ( = &lt; 10 % weight loss past month ) Must able avoid close household contact ( define share housing close physical contact ) least 3 week recombinant vaccinia vaccination individual active history eczema eczematoid skin disorder Must able avoid close household contact ( define share housing close physical contact ) least 3 week recombinant vaccinia vaccination unresolved acute , chronic , exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) Must able avoid close household contact ( define share housing close physical contact ) least 3 week recombinant vaccinia vaccination follow individual : pregnant nursing woman ; child = &lt; 5 year age ; immunodeficient immunosuppressed individual ( disease therapy ) , include HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study participation No concurrent serious medical illness would preclude study participation No concurrent biologic therapy No concurrent immunotherapy At least 6 week since prior nitrosoureas mitomycin Prior docetaxel allow ( part I ) No prior docetaxel ( part II ) No concurrent chemotherapy No concurrent systemic steroid except follow : physiologic dos systemic steroid replacement therapy local ( topical , nasal , inhale ) steroid use concurrent steroid eye drop premedication prior docetaxel No concurrent hormonal therapy No prior radiotherapy &gt; 50 % nodal group More 21 day since prior major surgery No prior splenectomy Recovered prior therapy At least 34 week since prior cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>